One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.

If you are looking for guidance based on this study's results:

Lenalidomide was the primary drug used for maintenance in this study. Key Findings:

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.

Ifm_05-may 2022 -

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.

If you are looking for guidance based on this study's results: IFM_05-May 2022

Lenalidomide was the primary drug used for maintenance in this study. Key Findings:

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. One critical finding was an increased risk of

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. Key Findings: The study demonstrated a clear overall

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.